docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-2-40-45docru-62Research ArticleТЕРАПИЯINTERNAL MEDICINEКлинические аспекты новой коронавирусной инфекцииClinical aspects of a new coronavirus infectionhttps://orcid.org/0000-0003-2019-2954ЕлисееваЛ. Ю.EliseevaL. Yu.

Елисеева Людмила Юрьевна — аспирант кафедры госпитальной терапии и общей врачебной практики имени В.Г. Вогралика

603005, г. Нижний Новгород

luu_muu@mail.ruhttps://orcid.org/0000-0001-7581-4138БоровковаН. Ю.BorovkovaN. Yu.

Боровкова Наталья Юрьевна  — д. м. н., доцент, профессор кафедры госпитальной терапии и общей врачебной практики имени В.Г. Вогралика 

603005, г. Нижний Новгород

borovkov-nn@mail.ruhttps://orcid.org/0000-0003-0414-9104ЗубеевП. С.ZubeevP. S.

Зубеев Павел Сергеевич — д. м. н., профессор, заведующий кафедрой скорой медицинской помощи 

603005, г. Нижний Новгород

mlpu33@mail.ruЗубееваГ. Н.ZubeevaG. N.

Зубеева Галина Николаевна — к. м. н., доцент кафедры скорой медицинской помощи

603005, г. Нижний Новгород

gzubeeva@yandex.ruФГБОУ ВО «Приволжский исследовательский медицинский университет» Министерства здравоохранения Российской Федерации; ГБУЗ НО «Городская больница № 33»РоссияPrivolzhsky State Medical University of the Ministry of Health of the Russian Federation; City Hospital No. 33Russian FederationФГБОУ ВО «Приволжский исследовательский медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияPrivolzhsky State Medical University of the Ministry of Health of the Russian FederationRussian Federation202215022025212ТЕРАПИЯ4045Copyright © Елисеева Л.Ю., Боровкова Н.Ю., Зубеев П.С., Зубеева Г.Н., 20252025Елисеева Л.Ю., Боровкова Н.Ю., Зубеев П.С., Зубеева Г.Н.Eliseeva L.Y., Borovkova N.Y., Zubeev P.S., Zubeeva G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/62Цель обзора

Цель обзора: провести анализ имеющихся данных об этиологии, патогенезе, диагностике и лечении новой коронавирусной инфекции.

Основные положения

Основные положения. В 2020 г. весь мир охватила пандемия нового вирусного заболевания, получившего название COVID-19. Нами были рассмотрены аспекты этиологии, патогенеза, диагностики, а также лечения данной инфекции. Одним из наиболее сложных вопросов является терапия COVID-19, так как течение заболевания усугубляет развитие цитокинового шторма.

Заключение

Заключение. При выборе тактики лечения пациента следует всесторонне оценивать возможные неблагоприятные явления, стремясь при этом максимально сократить их частоту.

Objective of the Review

Objective of the Review: to analyze the available data on the etiology, pathogenesis, diagnosis and treatment of a new coronavirus infection.

Key points

Key points. In 2020, the whole world was engulfed by a pandemic of a new viral disease, which was called the coronavirus disease СOVID-19. We have considered aspects of the etiology, pathogenesis, diagnosis, and treatment of this infection. One of the most difficult issues is the therapy of COVID-19, since the course of the disease exacerbates the development of a cytokine storm.

Conclusion

Conclusion. When choosing a patient's treatment tactics, it is necessary to comprehensively assess possible adverse events, strive to minimize their occurrence.

новая коронавирусная инфекцияCOVID-19ангиотензинпревращающий фермент 2цитокиновый штормnew coronavirus infectionCOVID-19angiotensin i converting enzyme 2cytokine stormReferencesMalik Y.A. Properties of coronavirus and SARS-CoV-2. Malays. J. Pathol. 2020; 42(1): 3–11.Malik Y.A. Properties of coronavirus and SARS-CoV-2. Malays. J. Pathol. 2020; 42(1): 3–11.Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5(4): 536–44. DOI: 10.1038/s41564-020-0695-zCoronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5(4): 536–44. DOI: 10.1038/s41564-020-0695-zWan Y., Shang J., Graham R. et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020; 94(7): e00127–20. DOI: 10.1128/jvi.00127-20Wan Y., Shang J., Graham R. et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020; 94(7): e00127–20. DOI: 10.1128/jvi.00127-20Успенская Ю.А., Комлева Ю.К., Горина Я.В. и др. Полифункциональность CD147 и новые возможности для диагности ки и терапии. Сибирское медицинское обозрение. 2018; 4: 22–30. [Uspenskaya Yu.A., Komleva Yu.K., Gorina Ya.V. et al. CD147 polyfunctionality and new diagnostic and therapy opportunities. Siberian Medical Review. 2018; 4: 22–30. (in Russian)]. DOI: 10.20333/2500136-2018-4-22-30Успенская Ю.А., Комлева Ю.К., Горина Я.В. и др. Полифункциональность CD147 и новые возможности для диагности ки и терапии. Сибирское медицинское обозрение. 2018; 4: 22–30. [Uspenskaya Yu.A., Komleva Yu.K., Gorina Ya.V. et al. CD147 polyfunctionality and new diagnostic and therapy opportunities. Siberian Medical Review. 2018; 4: 22–30. (in Russian)]. DOI: 10.20333/2500136-2018-4-22-30Warren T.K., Jordan R., Lo M.K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594): 381–5. DOI: 10.1038/nature17180Warren T.K., Jordan R., Lo M.K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594): 381–5. DOI: 10.1038/nature17180Никифоров В.В., Колобухина Л.В., Сметанина С.В. и др. Новая коронавирусная инфекция (COVID-19): этиология, эпидемиология, клиника, диагностика, лечение и профилактика. М.; 2020. 48 с. [Nikiforov V.V., Kolobuhina L.V., Smetanina S.V. et al. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. M.; 2020. 48 p. (in Russian)]Никифоров В.В., Колобухина Л.В., Сметанина С.В. и др. Новая коронавирусная инфекция (COVID-19): этиология, эпидемиология, клиника, диагностика, лечение и профилактика. М.; 2020. 48 с. [Nikiforov V.V., Kolobuhina L.V., Smetanina S.V. et al. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. M.; 2020. 48 p. (in Russian)]Wang K.E., Chen W., Zhang Z. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020; 5(1): 1–10. DOI: 10.1038/s41392-020-00426-xWang K.E., Chen W., Zhang Z. et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020; 5(1): 1–10. DOI: 10.1038/s41392-020-00426-xHoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Сell. 2020; 181(2): 271–80.e8. DOI: 10.1016/j.cell.2020.02.052Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Сell. 2020; 181(2): 271–80.e8. DOI: 10.1016/j.cell.2020.02.052Беляков Н.А., Рассохин В.В., Ястребова Е.Б.. Коронавирусная инфекция COVID-19. Природа вируса, патогенез, клинические проявления. Сообщение 1. ВИЧ-инфекция и иммуносупрессии. 2020; 12(1): 7–21. [Belyakov N.A., Rassohin V.V., Yastrebova E.B. Coronavirus infectious disease COVID-19. Nature of virus, pathogenesis, clinical manifestations. Report 1. HIV Infection and Immunosuppressive Disorders. 2020; 12(1): 7–21. (in Russian)]. DOI: 10.22328/2077-9828-2020-12-1-7-21Беляков Н.А., Рассохин В.В., Ястребова Е.Б.. Коронавирусная инфекция COVID-19. Природа вируса, патогенез, клинические проявления. Сообщение 1. ВИЧ-инфекция и иммуносупрессии. 2020; 12(1): 7–21. [Belyakov N.A., Rassohin V.V., Yastrebova E.B. Coronavirus infectious disease COVID-19. Nature of virus, pathogenesis, clinical manifestations. Report 1. HIV Infection and Immunosuppressive Disorders. 2020; 12(1): 7–21. (in Russian)]. DOI: 10.22328/2077-9828-2020-12-1-7-21Tisoncik J.R., Korth M.J., Simmons C.P. et al. Into the eye of the cytokine storm. Microbi. Mol. Biol. Rev. 2012; 76(1): 16–32. DOI: 10.1128/MMBR.05015-11Tisoncik J.R., Korth M.J., Simmons C.P. et al. Into the eye of the cytokine storm. Microbi. Mol. Biol. Rev. 2012; 76(1): 16–32. DOI: 10.1128/MMBR.05015-11Галкин А.А., Демидова В.С. Центральная роль нейтрофилов в патогенезе синдрома острого повреждения легких (острый респираторный дистресс-синдром). Успехи современной биологии. 2014; 134(4): 377–94. [Galkin A.A., Demidova V.S. The central role of neutrophils in pathogenesis of acute lung injury syndrome (ALI/ ARDS). Biology Bulletin Reviews. 2014; 134(4): 377–94. (In Russian)]Галкин А.А., Демидова В.С. Центральная роль нейтрофилов в патогенезе синдрома острого повреждения легких (острый респираторный дистресс-синдром). Успехи современной биологии. 2014; 134(4): 377–94. [Galkin A.A., Demidova V.S. The central role of neutrophils in pathogenesis of acute lung injury syndrome (ALI/ ARDS). Biology Bulletin Reviews. 2014; 134(4): 377–94. (In Russian)]Herold S., Steinmueller M., von Wulffen W. et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage expressed TNF-related apoptosis-inducing ligand. J. Exp. Med. 2008; 205(13): 3065–77. DOI: 10.1084/jem.20080201Herold S., Steinmueller M., von Wulffen W. et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage expressed TNF-related apoptosis-inducing ligand. J. Exp. Med. 2008; 205(13): 3065–77. DOI: 10.1084/jem.20080201Zheng S., Fan J., Yu F. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ. 2020; 369: m1443. DOI: 10.1136/bmj.m1443Zheng S., Fan J., Yu F. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ. 2020; 369: m1443. DOI: 10.1136/bmj.m1443Wang W., Xu Y., Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18): 1843–4. DOI: 10.1001/jama.2020.3786Wang W., Xu Y., Gao R. et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18): 1843–4. DOI: 10.1001/jama.2020.3786Гудима Г.О., Хаитов Р.М., Кудлай Д.А. и др. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции. Иммунология. 2021; 42(3): 198–210. [Gudima G.O., Khaitov R.M., Kudlay D.A. et al. Molecular-immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunology. 2021; 42(3): 198–210. (in Russian)]. DOI: 10.33029/0206-4952-2021-42-3-198-210Гудима Г.О., Хаитов Р.М., Кудлай Д.А. и др. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции. Иммунология. 2021; 42(3): 198–210. [Gudima G.O., Khaitov R.M., Kudlay D.A. et al. Molecular-immunological aspects of diagnostics, prevention and treatment of coronavirus infection. Immunology. 2021; 42(3): 198–210. (in Russian)]. DOI: 10.33029/0206-4952-2021-42-3-198-210van Kampen J.J., van de Vijver D.A., Fraaij P.L. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 2021; 12(1): 267. DOI: 10.1038/s41467-020-20568-4van Kampen J.J., van de Vijver D.A., Fraaij P.L. et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat. Commun. 2021; 12(1): 267. DOI: 10.1038/s41467-020-20568-4Long D.R., Gombar S,. Hogan C.A. et al. Occurrence and timing of subsequent severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction positivity among initially negative patients. Clin. Infect. Dis. 2021; 72(2): 323–326. DOI: https://doi.org/10.1093/cid/ciaa722Long D.R., Gombar S,. Hogan C.A. et al. Occurrence and timing of subsequent severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction positivity among initially negative patients. Clin. Infect. Dis. 2021; 72(2): 323–326. DOI: https://doi.org/10.1093/cid/ciaa722Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med. 2020; 382(13): 1199–1207. DOI: 10.1056/NEJMoa2001316Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med. 2020; 382(13): 1199–1207. DOI: 10.1056/NEJMoa2001316Zhao J., Yuan Q., Wang H. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 2020; 71(16): 2027–34. DOI: 10.1093/cid/ciaa344Zhao J., Yuan Q., Wang H. et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin. Infect. Dis. 2020; 71(16): 2027–34. DOI: 10.1093/cid/ciaa344Kanji J.N., Zelyas N., MacDonald C. et al. False negative rate of COVID-19 PCR testing: a discordant testing analysis. Virol. J. 2021; 18(1): 13. DOI: 10.1186/s12985-021-01489-0Kanji J.N., Zelyas N., MacDonald C. et al. False negative rate of COVID-19 PCR testing: a discordant testing analysis. Virol. J. 2021; 18(1): 13. DOI: 10.1186/s12985-021-01489-0Khan M.S., Shahid I., Anker S.D. et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020; 18(1): 403. DOI: 10.1186/s12916-020-01816-2Khan M.S., Shahid I., Anker S.D. et al. Cardiovascular implications of COVID-19 versus influenza infection: a review. BMC Med. 2020; 18(1): 403. DOI: 10.1186/s12916-020-01816-2Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020; 209: 107512. DOI: 10.1016/j.pharmthera.2020.107512Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol. Ther. 2020; 209: 107512. DOI: 10.1016/j.pharmthera.2020.107512Joshi S., Parkar J., Ansari A. et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 2021; 102: 501–8. DOI: 10.1016/j.ijid.2020.10.069Joshi S., Parkar J., Ansari A. et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 2021; 102: 501–8. DOI: 10.1016/j.ijid.2020.10.069Ghasemnejad-Berenji M., Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res. (Stuttg.). 2021; 71(3): 166–70. DOI: 10.1055/a-1296-7935Ghasemnejad-Berenji M., Pashapour S. Favipiravir and COVID-19: a simplified summary. Drug Res. (Stuttg.). 2021; 71(3): 166–70. DOI: 10.1055/a-1296-7935Pizzorno A., Padey B., Dubois J. et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020; 181: 104878. DOI: 10.1016/j.antiviral.2020.104878Pizzorno A., Padey B., Dubois J. et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. Antiviral Res. 2020; 181: 104878. DOI: 10.1016/j.antiviral.2020.104878Williamson B.N., Feldmann F., Schwarz B. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020; 585(7824): 273–6. DOI: 10.1038/s41586-020-2423-5Williamson B.N., Feldmann F., Schwarz B. et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020; 585(7824): 273–6. DOI: 10.1038/s41586-020-2423-5Beigel J.H., Tomashek K.M., Dodd L.E. et al. Remdesivir for the treatment of COVID-19 — final report. N. Engl. J. Med. 2020; 383(19): 1813–1826. DOI: 10.1056/NEJMc2022236Beigel J.H., Tomashek K.M., Dodd L.E. et al. Remdesivir for the treatment of COVID-19 — final report. N. Engl. J. Med. 2020; 383(19): 1813–1826. DOI: 10.1056/NEJMc2022236Ader F., Bouscambert-Duchamp M., Hites M. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2022; 22(2): 209–21. DOI: 10.1016/S1473-3099(21)00485-0Ader F., Bouscambert-Duchamp M., Hites M. et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2022; 22(2): 209–21. DOI: 10.1016/S1473-3099(21)00485-0Камкин Е.Г. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 14. Временные методические рекомендации М.; 2021. [Kamkin E.G. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 14 Interim Guidelines. M.; 2021. (in Russian)]Камкин Е.Г. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 14. Временные методические рекомендации М.; 2021. [Kamkin E.G. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 14 Interim Guidelines. M.; 2021. (in Russian)]Malin J.J., Suárez I., Priesner V. et al. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 2020; 34(1): e00162– 20. DOI: 10.1128/CMR.00162-20Malin J.J., Suárez I., Priesner V. et al. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 2020; 34(1): e00162– 20. DOI: 10.1128/CMR.00162-20Pinto D., Park Y.J., Beltramello M. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815): 290–5. DOI: 10.1038/s41586-020-2349-yPinto D., Park Y.J., Beltramello M. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020; 583(7815): 290–5. DOI: 10.1038/s41586-020-2349-yGupta A., Gonzalez-Rojas Y., Juarez E. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 2021; 385(21): 1941–1950. DOI: 10.1056/NEJMoa2107934Gupta A., Gonzalez-Rojas Y., Juarez E. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 2021; 385(21): 1941–1950. DOI: 10.1056/NEJMoa2107934Brobst B., Borger J. Benefits and risks of administering monoclonal antibody therapy for coronavirus (COVID-19). Treasure Island; 2021.Brobst B., Borger J. Benefits and risks of administering monoclonal antibody therapy for coronavirus (COVID-19). Treasure Island; 2021.Annane D., Bellissant E., Bollaert P.E. et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst. Rev. 2019; 12(12): :CD002243. DOI: 10.1002/14651858.CD002243.pub4Annane D., Bellissant E., Bollaert P.E. et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst. Rev. 2019; 12(12): :CD002243. DOI: 10.1002/14651858.CD002243.pub4RECOVERY Collaborative Group; Horby P., Lim W.S. et al. Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N. Engl. J. Med. 2020; 384(8): 693–704. DOI: 10.1056/NEJMoa2021436RECOVERY Collaborative Group; Horby P., Lim W.S. et al. Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N. Engl. J. Med. 2020; 384(8): 693–704. DOI: 10.1056/NEJMoa2021436WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne J.A., Murthy S. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324(13): 1330–41. DOI: 10.1001/jama.2020.17023WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne J.A., Murthy S. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324(13): 1330–41. DOI: 10.1001/jama.2020.17023Rana M.A., Siddiqui M.H., Raza S. et al. Incidence of steroid-induced diabetes in COVID-19 patients. Pakistan J. M. Health Sci. 2021; 15(10): 2595–6.Rana M.A., Siddiqui M.H., Raza S. et al. Incidence of steroid-induced diabetes in COVID-19 patients. Pakistan J. M. Health Sci. 2021; 15(10): 2595–6.Mishra G.P., Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir. Med. 2021; 9(1): e8. DOI: 10.1016/S2213-2600(20)30530-0Mishra G.P., Mulani J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. Lancet Respir. Med. 2021; 9(1): e8. DOI: 10.1016/S2213-2600(20)30530-0Антонов В.Н., Игнатова Г.Л., Прибыткова О.В. и др. Опыт применения олокизумаба у больных COVID-19. Терапевтический архив. 2020; 92(12): 148–54. [Antonov V.N., Ignatova G.L., Pribytkova O.V. et al. Experience of olokizumab use in COVID-19 patients. Therapeutic Archive. 2020; 92(12): 148–54. (in Russian)]. DOI: 10.26442/0040-3660.2020.12.200522Антонов В.Н., Игнатова Г.Л., Прибыткова О.В. и др. Опыт применения олокизумаба у больных COVID-19. Терапевтический архив. 2020; 92(12): 148–54. [Antonov V.N., Ignatova G.L., Pribytkova O.V. et al. Experience of olokizumab use in COVID-19 patients. Therapeutic Archive. 2020; 92(12): 148–54. (in Russian)]. DOI: 10.26442/0040-3660.2020.12.200522Scheinecker C., Smolen J., Yasothan U. et al. Tocilizumab. Nat. Rev. Drug Dis. 2009; 8(4): 273–4. DOI: 10.1038/nrd2863Scheinecker C., Smolen J., Yasothan U. et al. Tocilizumab. Nat. Rev. Drug Dis. 2009; 8(4): 273–4. DOI: 10.1038/nrd2863Mahroum N., Watad A., Bridgewood C. et al. Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic. Int. J. Environ. Res. Public Health. 2021; 18(17): 9149. DOI: 10.3390/ijerph18179149Mahroum N., Watad A., Bridgewood C. et al. Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic. Int. J. Environ. Res. Public Health. 2021; 18(17): 9149. DOI: 10.3390/ijerph18179149Hermine O., Mariette X., Tharaux P.L. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern. Med. 2021; 181(1): 32–40. DOI: 10.1001/jamainternmed.2020.6820Hermine O., Mariette X., Tharaux P.L. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern. Med. 2021; 181(1): 32–40. DOI: 10.1001/jamainternmed.2020.6820Kaur U., Chakrabarti S.S., Patel T.K. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. Ther. Adv. Drug Saf. 2021; 12: 20420986211011345. DOI: 10.1177/20420986211011345Kaur U., Chakrabarti S.S., Patel T.K. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis. Ther. Adv. Drug Saf. 2021; 12: 20420986211011345. DOI: 10.1177/20420986211011345Minz M.M., Bansal M., Kasliwal R.R. Statins and SARS-CoV-2 disease: current concepts and possible benefits. Diabetes Metab. Syndr. 2020; 14(6): 2063–2067. DOI: 10.1016/j.dsx.2020.10.021Minz M.M., Bansal M., Kasliwal R.R. Statins and SARS-CoV-2 disease: current concepts and possible benefits. Diabetes Metab. Syndr. 2020; 14(6): 2063–2067. DOI: 10.1016/j.dsx.2020.10.021Ganjali S., Bianconi V., Penson P.E. et al. Commentary: statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism. 2020; 113: 154375. DOI: 10.1016/j.metabol.2020.154375Ganjali S., Bianconi V., Penson P.E. et al. Commentary: statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism. 2020; 113: 154375. DOI: 10.1016/j.metabol.2020.154375Masana L., Correig E., Rodríguez-Borjabad C. et al. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. Eur. Heart J. Cardiovasc. Pharmacother. 2020; 8(2): 157– 164. DOI: 10.1093/ehjcvp/pvaa128Masana L., Correig E., Rodríguez-Borjabad C. et al. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. Eur. Heart J. Cardiovasc. Pharmacother. 2020; 8(2): 157– 164. DOI: 10.1093/ehjcvp/pvaa128Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. DOI: 10.1016/S0140-6736(20)30566-3Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054–62. DOI: 10.1016/S0140-6736(20)30566-3Bikdeli B., Madhavan M.V., Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2020; 75(23): 2950–73. DOI: 10.1016/j.jacc.2020.04.031Bikdeli B., Madhavan M.V., Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2020; 75(23): 2950–73. DOI: 10.1016/j.jacc.2020.04.031Poor H.D., Ventetuolo C.E., Tolbert T. et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin. Transl. Med. 2020; 10(2): e44. DOI: 10.1002/ctm2.44Poor H.D., Ventetuolo C.E., Tolbert T. et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin. Transl. Med. 2020; 10(2): e44. DOI: 10.1002/ctm2.44Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020; 314: 58–62. DOI: 10.1016/j.atherosclerosis.2020.10.014Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020; 314: 58–62. DOI: 10.1016/j.atherosclerosis.2020.10.014Meizlish M.L., Goshua G., Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am. J. Hematol. 2021; 96(4): 471–9. DOI: 10.1002/ajh.26102Meizlish M.L., Goshua G., Liu Y. et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am. J. Hematol. 2021; 96(4): 471–9. DOI: 10.1002/ajh.26102

The authors declare that there are no conflicts of interest present.